**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a single-center case series involving 18 solid organ transplant (SOT) recipients who had been routinely following at a hospital in Spain and who had been diagnosed with coronavirus disease (COVID-19) from 05 March 2020 to 23 March 2020, a 65-year-old man was described, who developed nephrotoxicity manifesting as renal failure during immunosuppressants therapy with tacrolimus.

The man (patient 8 from Table 1 of the article), who had undergone kidney transplant, had been receiving maintenance immunosuppressants therapy with tacrolimus \[*dosage and route not stated*\], along with prednisone and mycophenolic acid. His medical history was significant for chronic interstitial nephritis, hypertension, diabetes and obstructive sleep apnea-hypopnea syndrome. He presented with fever, shortness of breath, cough and myalgia. Eventually, he was diagnosed with COVID-19 on 23 Mar 2020. Therefore, he started receiving off-label treatment with oral lopinavir/ritonavir 200mg/100mg, twice daily and oral hydroxychloroquine 400mg twice daily for the first day, followed by 200mg twice daily from the second day and was scheduled to be administered for 5 days. The therapy with lopinavir/ritonavir was prematurely discontinued due to severe gastrointestinal symptoms \[*aetiology of gastrointestinal symptoms not stated*\]. On day 11 of onset of COVID-19 symptoms, the tacrolimus levels were found to be supra-therapeutic 49.8 ng/mL \[*aetiology for supra-therapeutic level of tacrolimus not stated*\], that ultimately resulted in tacrolimus-induced nephrotoxicity in the form of renal failure \[*duration of treatment to reaction onset not stated*\].

The man consequently required four sessions of haemodialysis.
